European Medicines Agency (EMA) Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting, London - Main contents

During the first day of the meeting digital media and health topics will be discussed, including recent learnings and trends around mHealth, social media, real-word evidence and electronic product information. On the second day, PCWP/HCPWP members will have a chance to hear the latest on EMA relocation, clinical data publication policy and implementation of Clinical Trial Regulation; followed by discussion on findings of the survey on “additional monitoring” awareness. Other topics for discussion include EMA-Heads of Medicines Agencies (HMA) collaboration on shortages and availability of medicines and EMA- European network for health technology assessment (EUnetHTA) collaboration on engagement with patients and healthcare professionals in assessment activities.

The European Medicines Agency (EMA) is a decentralised body of the European Union with headquarters in Amsterdam. Its main responsibility is the protection and promotion of public and animal health, through the evaluation and supervision of medicines for human and veterinary use.

The EMA is responsible for the scientific evaluation of applications for European marketing authorisation for medicinal products (centralised procedure). Under the centralised procedure, companies submit one single marketing authorisation application to the EMA.